4Wong CS,Jelacic S,Habeeb RL,et al.The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. New England Journal of Medicine, The . 2000
6Wallace CK, Anderson PN, Brown TC, et al. Optimal antibiotic therapy. Bull World Health Org, 1968, 39 : 239- 245.
7Fraser GL, Stoqsdill P, Dickens JD Jr, et al. Antibiotic optimization. An evaluation of safety and economic outcomes. Arch Intern Med, 1997, 157: 1659- 1694.
8Craig WA. Pharmacokinetic/phannacodynamic parameters: rational for antibacterial dosing of mice and men. Clin Infect Dis, 1998, 26:1-12.
9Owens RC, Ammbrose PG, Nightingale CH, et al. ed. Antibiotic Optimization: concepts and strategies in clinitical practice New York: Marcel Dekker, 2005.
10Levin BR, Anita R, Berliner E, et al. Resistance to antimicrobial chemotherapy: A prescription for research and action. Am J Med Sci, 1998, 315: 87- 94.